New York State Psychiatric Institute clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 433 studies whose lead sponsor is New York State Psychiatric Institute. 25 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the New York State Psychiatric Institute studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions New York State Psychiatric Institute leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Depressive Disorder75Depression73Opioid-Related Disorders43Depressive Disorder, Major37Cocaine-Related Disorders31Schizophrenia28Psychotic Disorders27Obsessive-Compulsive Disorder24Substance-Related Disorders23Anorexia Nervosa21Bipolar Disorder19Alcoholism18Anorexia18Attention Deficit Disorder with Hyperactivity15Dysthymic Disorder15Mental Disorders13Bulimia11Bulimia Nervosa10Heroin Dependence10
Studies
Recruiting first, then most recently updated. Showing 50 of 433. Browse all 433 →
- An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia NervosaNot yet recruitingNCT06518941Phase 2
- rTMS and Cognitive-behavioral Therapy for Cocaine Use DisorderRecruitingNCT05974202Not applicable
- Mindfulness-Based Substance Use Prevention (MINDS-UP)Not yet recruitingNCT06593470Not applicable
- Brief Intervention Addressing Stigma Among Parents of Children With Mental Health ProblemsNot yet recruitingNCT07594730Not applicable
- Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderRecruitingNCT05999240Phase 2
- Computer - Based Treatment for Social Anxiety DisorderRecruitingNCT04663724Not applicable
- Glutamatergic Mechanisms: Aim2RecruitingNCT05401227Phase 1
- Air Pollution and Development in the Boricua Youth StudyEnrolling by invitationNCT05368493Not applicable
- Sleep Interventions and Neurocognitive OutcomesNot yet recruitingNCT05987007Not applicable
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal ThoughtsNot yet recruitingNCT07139106Phase 4
- Helping Adults With Obsessive-Compulsive Disorder Succeed at WorkRecruitingNCT07124780Not applicable
- Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in SchizophreniaNot yet recruitingNCT07715253Phase 1
- Effects of rTMS on Food Choice in Anorexia NervosaRecruitingNCT05918835Not applicable
- A Multimodal Imaging Study of Dopamine in Early PsychosisNot yet recruitingNCT06977308Phase 1
- A PET/MRI Study of Cobenfy on Dopamine Transmission in SchizophreniaRecruitingNCT07423546Phase 1/2
- Exercise and Olanzapine-samidorphanRecruitingNCT06740890Phase 4
- Scaling up e-Connect in Juvenile Probation SettingsRecruitingNCT05541926Not applicable
- Relapse Prevention and Changing Habits in Anorexia NervosaRecruitingNCT04810624Not applicable
- Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderRecruitingNCT05011266Phase 2/3
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical TrialRecruitingNCT05208190Phase 4
- Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)RecruitingNCT05477901Not applicable
- Clinical Trials of Multivalent Opioid Vaccine ComponentsRecruitingNCT04458545Phase 1/2
- Shared Decision Making for Antipsychotic MedicationsNot yet recruitingNCT05416658Not applicable
- Treating Common Mental Disorders in Women in Mozambique by Addressing Intimate Partner Violence in CouplesNot yet recruitingNCT06252909Not applicable
- The Role of Brief Potent Glutamatergic Modulation in Addressing Problem DrinkingRecruitingNCT04084860Phase 2
- Facilitating Opioid Care ConnectionsActive, not recruitingNCT04216719Not applicable
- Attaining and Maintaining Wellness in Obsessive-compulsive DisorderCompletedNCT01686087Not applicable
- Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in HumansSuspendedNCT04596644Phase 2
- Sublingual Buprenorphine Through Telemedicine vs In-Person Care as UsualWithdrawnNCT05339256Phase 2
- Repeated Administration of Cannabis Varying in THC and CBDSuspendedNCT05563948Phase 2
- Influence of Tobacco Use on Cannabis UseSuspendedNCT03766971Phase 2
- Effectiveness and Cost-Effectiveness of Depression Treatment for Individuals With TB in South AfricaSuspendedNCT05091580Not applicable
- A Trial of Guanfacine-er for Cannabis Use DisorderCompletedNCT05273567Phase 2
- Leveraging Social Networks to Increase COVID-19 Testing UptakeCompletedNCT04873401Not applicable
- Personalized and Scalable Cognitive Remediation ApproachesCompletedNCT01945333Not applicable
- Using mHealth to Optimize Pharmacotherapy RegimensCompletedNCT04248517Not applicable
- Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)Active, not recruitingNCT04589208Phase 1/2
- Boricua Youth Study COVID-19 Coping Intervention StudyCompletedNCT05444881Not applicable
- OnTrackNY's Learning Healthcare SystemSuspendedNCT04021719
- The Cultural Formulation Interview-Engagement AidCompletedNCT03044145Not applicable
- Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native CommunitiesCompletedNCT04958798Not applicable
- Scaffolding of Brain OperationsSuspendedNCT05412901Not applicable
- IM Ketamine vs Midazolam for Suicidal ER PatientsSuspendedNCT04640636Phase 4
- Improving Alcohol Use Disorder Treatment for Gender Minority PopulationsSuspendedNCT05070793Not applicable
- Web-based Addiction Treatment: Cultural Adaptation With American IndiansCompletedNCT03363256Not applicable
- Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress DisorderCompletedNCT00739765Not applicable
- Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)CompletedNCT02645929
- D-serine AudRem: R33 PhaseSuspendedNCT05046353Phase 1/2
- Dopamine D3 Receptor Occupancy in Bipolar DepressionWithdrawnNCT05060549Phase 4
- Sublingual Dexmedetomidine for Treating Opioid WithdrawalActive, not recruitingNCT05712707Phase 1/2